Breaking Finance News

Meridian Bioscience, Inc. (NASDAQ:VIVO) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Boasting a price of $19.59, Meridian Bioscience, Inc. (NASDAQ:VIVO) traded 0.10% higher on the day. With the last stock price close down -1.90% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Meridian Bioscience, Inc. has recorded a 50-day average of $19.31 and a two hundred day average of $19.66. Volume of trade was up over the average, with 381,374 shares of VIVO changing hands over the typical 198,141

Zacks Investment Research has downgraded Meridian Bioscience, Inc. (NASDAQ:VIVO) to Sell in a statement released on Wednesday September 28, 2016.

On 3/28/2016, Canaccord Genuity released a statement for Meridian Bioscience, Inc. (NASDAQ:VIVO) bumped up the target price from $18.00 to $19.00 that suggested a downside of -0.04%.

Performance Chart

Meridian Bioscience, Inc. (NASDAQ:VIVO)

With a total market value of $0, Meridian Bioscience, Inc. has price-earnings ratio of 22.96 with a one year low of $17.21 and a one year high of $21.49 .

A total of 4 equity analysts have released a ratings update on VIVO. zero equity analysts rating the company a strong buy, two equity analysts rating the company a buy, three equity analysts rating the company a hold, two equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $19.00.

Brief Synopsis About Meridian Bioscience, Inc. (NASDAQ:VIVO)

Meridian Bioscience, Inc. (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *